预约演示
更新于：2025-05-16
Tobramycin Sulfate
硫酸妥布霉素
更新于：2025-05-16
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1975-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H39N5O13S |
InChIKeyZEUUPKVZFKBXPW-TWDWGCDDSA-N |
CAS号49842-07-1 |
关联
7
项与 硫酸妥布霉素 相关的临床试验NCT04662632
A Randomized Controlled Trial of Alternating Irrigation of Vancomycin Hydrochloride and Tobramycin Sulfate in Patients Undergoing Two-Stage Exchange Arthroplasty for Periprosthetic Joint Infection (PJI) of the Hip or Knee
NCT03721328
A Phase 2 Multicenter Feasibility Trial to Evaluate Safety and Efficacy in Patients Treated for Hip or Knee Prosthetic Joint Infection (PJI) With Alternating Irrigation of Vancomycin Hydrochloride (HCl) and Tobramycin Sulfate in Two-Stage Exchange Arthroplasty
NCT03066453
Evaluation of an Antibiotic Treatment With 14 Days of Intravenous Tobramycin Versus the Same Antibiotic Associated With 5 Days of Intravenous Tobramycin Followed by Tobramycin Aerosol for 9 Days in Cystic Fibrosis.
100 项与 硫酸妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 硫酸妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 硫酸妥布霉素 相关的专利（医药）
登录后查看更多信息
16,114
项与 硫酸妥布霉素 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
Targeted inhibition of PqsR in Pseudomonas aeruginosa PAO1 quorum-sensing network by chalcones as promising antibacterial compounds
Article
作者: Soheili, Vahid ; Tajani, Amineh Sadat ; Bazzaz, Bibi Sedigheh Fazly ; Rezaei, Tahoura ; Hashemi, Maryam ; Ghodsi, Razieh ; Arami, Negin
BACKGROUND:
Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and the virulence factors, on the other hand, contribute to fatal infection and other recalcitrant phenotypic characteristics. These capabilities are harmonized through cell-cell communication called Quorum Sensing (QS), which results in gene expression regulation via three major interconnected circuits: las, rhl, and pqs system. Pqs circuit specificity in P. aeruginosa made this system an attractive target for antipseudomonal therapy. The current study focuses on novel chalcone derivatives that attenuate P. aeruginosa's pathogenicity by inhibiting the QS system. Chalcones are included in the flavonoid class of phenolic compounds. This family forms one of the greatest groups of bioactive natural products.
METHOD:
The chalcone derivatives's potential activity against the QS system was evaluated through biofilm inhibition, decreased virulence factors production, and gene expression.
RESULTS:
Among all the tested compounds, 5H and NMe2 chalcone derivatives reduced biofilm formation by 60.9% and 78.9%, respectively, and virulence factors production, including pyocyanin (decreased by 5H 30.9% and NMe2 30.7%) and pyoverdine (decreased by 5H 47.1% and NMe2 56.9%) and the QS gene expression (LasR, RhlR, and PqsR) more effectively than other derivatives.
CONCLUSION:
These chalcone compounds can be used as a supplement besides antimicrobial chemotherapy to attenuate pseudomonas pathogenicity.
2025-09-01TALANTA
Ultra-rapid, quantitative, label-free antibiotic susceptibility testing via optically detected purine metabolites
Article
作者: Ziegler, L D ; Fraiman, A
In order to facilitate the best antimicrobial prescribing practices and to help reduce the increasing global threat of antibiotic resistance, there is an urgent need for the development of novel and truly rapid (≤1 h) antibiotic susceptibility testing (AST) platforms. A 785 nm surface enhanced Raman spectroscopy (SERS) based phenotypic methodology is described that results in accurate minimum inhibitory concentration (MIC) determinations for all tested strain/antibiotic pairs. The SERS-AST procedure results in accurate MICs in ∼1 h, including a 30-min incubation period, and is effective for both Gram positive and negative species, and for antibiotics with different initial primary targets of antibiotic activity, and for both bactericidal and bacteriostatic antibiotics. The molecular level mechanism of this methodology is described. Bacterial SERS spectra are due to secreted purine nucleotide degradation products (principally adenine, guanine, xanthine and hypoxanthine) resulting from water washing induced bacterial stringent response and the resulting (p)ppGpp alarmone mediates nucleobase formation from unneeded tRNA and rRNA. The rewiring of metabolic responses resulting from the secondary metabolic effects of antibiotic exposure during the 30-min incubation period accounts for the dose dependence of the SERS spectral intensities which are used to accurately yield the MIC. This is the fastest demonstrated AST method yielding MICs.
2025-08-01TALANTA
Ultrasensitive detection of chloramphenicol using a performance-enhanced Fe/Zn-MIL-88B driven dual-mode biosensing platform
Article
作者: Wang, Yaohui ; Ouyang, Qin ; Liu, Shuangshuang ; Tu, Hanqing ; Xu, Linhui ; Mao, Keheng
Chloramphenicol (CAP) used in aquaculture poses a great threat to human health. In this study, a novel biosensing platform was proposed by Fe/Zn-MIL-88B with performance-enhanced for fluorescent/colorimetric dual-mode detection of CAP. Zinc was incorporated into the metal-organic framework to modulate its internal electronic structure, resulting in the formation of Fe/Zn-MIL-88B. This modification notably boosted its peroxidase-like activity, enhancing the colorimetric sensing capabilities. Simultaneously, Fe/Zn-MIL-88B exhibited excellent fluorescence quenching properties, when combined with upconversion nanomaterials and aptamers to enable a fluorescent sensing system. The composite materials were integrated into a three-dimensional folded microfluidic analyzer created a biosensing platform for ultrasensitive sensing of CAP. The results demonstrated that the dynamic response of the biosensing platform for CAP ranged from 0.5 to 1000 ng/mL, with the detection limits of 0.064 ng/mL (fluorescence) and 0.095 ng/mL (colorimetry), respectively. The work offers valuable insights into the further development of advanced biosensing platforms.
100 项与 硫酸妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 囊性纤维化 | 澳大利亚 | 2009-07-17 | |
| 下呼吸道感染 | 美国 | 2004-07-13 | |
| 脑膜炎 | 美国 | 2004-07-13 | |
| 腹膜炎 | 美国 | 2004-07-13 | |
| 脓毒症 | 美国 | 2004-07-13 | |
| 皮肤和皮肤结构感染 | 美国 | 2004-07-13 | |
| 泌尿道感染 | 美国 | 2004-07-13 | |
| 细菌感染 | 美国 | 1975-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 15 | 膚淵鏇齋構壓艱壓簾齋 = 獵構觸餘積積鑰獵淵範 願糧繭鏇鑰蓋襯鏇餘顧 (膚範顧壓糧餘製築觸鏇, 繭鏇鑰製淵構網獵繭選 ~ 齋膚觸選繭網網獵鏇餘) 更多 | - | 2021-12-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用